Bausch+Lomb's Xiidra/Miebo combo drop missed Phase 2 primary endpoint but CEO Brent Saunders calls it positive; Phase 3 planned with FDA's 15-day readout approval.
Bausch + Lomb’s dual-action drop for dry eye failed a Phase 2 study, the company exclusively told Endpoints News on Monday. But CEO Brent Saunders claims …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bausch + Lomb flops in ph. 2 with Xiidra and Miebo but advances combo to ph. 3
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
What's Going On With Bausch + Lomb Stock Tuesday? - Bausch & Lomb (NYSE:BLCO)
Fierce Pharma Asia—China's IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe's dermatology deal
Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry eye disease drugs Xiidra and Miebo. | Bausch +…
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a sustained-release GA implant.
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed…
PHOENIX — Most patients who used Xiidra eye drops had a “clinically meaningful” reduction in eye dryness by the 84th day of…
